Mounjaro maintenance dose: what patients should understand

The maintenance dose question

Once weight loss has plateaued on Mounjaro, a common question is whether the dose can be reduced — or whether a lower maintenance dose might preserve results without full-dose side effects and cost. The short answer: the evidence for maintenance dosing with tirzepatide is limited, and what exists is not encouraging about dose reduction as a standalone strategy.

What SURMOUNT-4 actually showed

SURMOUNT-4 is the most relevant trial. After a 36-week lead-in on tirzepatide, participants were randomised to continue or switch to placebo. Those who stopped regained substantially — approximately 14% body weight over 52 weeks — while those who continued maintained and extended their losses. By week 88, mean weight loss from baseline was 25.3% in the continuation arm versus 9.9% in the withdrawal arm. [1]

Crucially, SURMOUNT-4 did not test a reduced maintenance dose against full dose — it tested continuation versus withdrawal. The trial confirms that stopping tirzepatide after weight loss leads to regain. It does not tell us whether 5 mg can maintain what 15 mg achieved.

Can you drop to a lower dose to maintain?

There is genuine clinical uncertainty here. Some clinicians reduce from 10 or 15 mg to 5 mg for patients who have reached their goal and are tolerating treatment well. There is no RCT evidence that this preserves weight loss. What the pharmacology suggests is that tirzepatide's effect on appetite and weight is dose-dependent — lower doses provide less appetite suppression. [2] Whether any individual can maintain on a lower dose depends on how much of their weight management is pharmacologically driven versus behavioural.

A pragmatic approach: if dose reduction is being considered, structure it as an n-of-1 experiment with clear monitoring — weekly weight trend, hunger score, waist measurement — and a pre-agreed threshold at which dose is restored. Do not reduce dose and then wait to see what happens months later.

What NICE says about long-term prescribing

NICE guidance on Mounjaro (tirzepatide) for chronic weight management specifies criteria for continuation beyond two years: the patient must have maintained at least 5% weight loss from baseline. [3] This is not a maintenance dose question — it is a continuation question. The implication is that tirzepatide is positioned as a long-term medication for some patients, not a finite course. That is a significant reframe for patients who started treatment expecting to stop after reaching a target weight.

The cost and supply reality

Private Mounjaro costs approximately £150–200 per month depending on dose. For many patients the maintenance question is partly financial — can they sustain higher doses long-term? A dose reduction that preserves 80% of the benefit at half the cost is practically rational even if imperfectly evidenced. The alternative — stopping entirely and regaining — is more expensive in health terms even if it costs nothing financially.

What maintenance actually requires

Whether on a reduced dose or stopping entirely, sustainable maintenance requires three foundations that medication alone does not provide: lean mass preservation through resistance training; dietary structure anchored around protein; and consistent monitoring with a response plan. Medication without these foundations typically means regain when the medication changes. These foundations without medication typically means slower progress but more durable results. The strongest outcomes combine both.

A GLP-1 Exit Strategy Review maps the maintenance plan — including what dose change or cessation means for your specific situation — before you make a change.

When to involve your clinician

Any dose change on Mounjaro should be clinician-led if you have type 2 diabetes, are on other glucose-lowering medication, or have blood pressure medication. Dose changes affect these in ways that may not be immediately obvious.